Jazz Pharmaceuticals said on Tuesday that it had agreed to a settlement of $145 million to resolve a series of antitrust lawsuits related to its narcolepsy drug, Xyrem. Xyrem, a medication approved in the U.S., is used for the treatment …
Source: Claims Journal